Cargando…

Native-like SARS-CoV-2 Spike Glycoprotein Expressed by ChAdOx1 nCoV-19/AZD1222 Vaccine

Mostrar otras versiones (1)

[Image: see text] Vaccine development against the SARS-CoV-2 virus focuses on the principal target of the neutralizing immune response, the spike (S) glycoprotein. Adenovirus-vectored vaccines offer an effective platform for the delivery of viral antigen, but it is important for the generation of ne...

Descripción completa

Detalles Bibliográficos
Autores principales:	Watanabe, Yasunori, Mendonça, Luiza, Allen, Elizabeth R., Howe, Andrew, Lee, Mercede, Allen, Joel D., Chawla, Himanshi, Pulido, David, Donnellan, Francesca, Davies, Hannah, Ulaszewska, Marta, Belij-Rammerstorfer, Sandra, Morris, Susan, Krebs, Anna-Sophia, Dejnirattisai, Wanwisa, Mongkolsapaya, Juthathip, Supasa, Piyada, Screaton, Gavin R., Green, Catherine M., Lambe, Teresa, Zhang, Peijun, Gilbert, Sarah C., Crispin, Max
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Chemical Society 2021
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8043200/ https://www.ncbi.nlm.nih.gov/pubmed/34056089 http://dx.doi.org/10.1021/acscentsci.1c00080

Ejemplares similares

Native-like SARS-CoV-2 spike glycoprotein expressed by ChAdOx1 nCoV-19/AZD1222 vaccine
por: Watanabe, Yasunori, et al.
Publicado: (2021)

ChAdOx1 nCoV-19 (AZD1222) or nCoV-19-Beta (AZD2816) protect Syrian hamsters against Beta Delta and Omicron variants
por: van Doremalen, Neeltje, et al.
Publicado: (2022)

The ChAdOx1 vectored vaccine, AZD2816, induces strong immunogenicity against SARS-CoV-2 beta (B.1.351) and other variants of concern in preclinical studies
por: Spencer, Alexandra J, et al.
Publicado: (2022)

Reduced neutralisation of SARS-CoV-2 omicron B.1.1.529 variant by post-immunisation serum
por: Dejnirattisai, Wanwisa, et al.
Publicado: (2022)

An exploratory analysis of the response to ChAdOx1 nCoV-19 (AZD1222) vaccine in males and females
por: Marchevsky, Natalie Gabrielle, et al.
Publicado: (2022)

Antigenic characterization of SARS-CoV-2 Omicron subvariant BA.4.6
por: Dijokaite-Guraliuc, Aiste, et al.
Publicado: (2022)

Dengue virus sero-cross-reactivity drives antibody-dependent enhancement of infection with zika virus
por: Dejnirattisai, Wanwisa, et al.
Publicado: (2016)

Anti-Dengue E-dimer epitope human antibodies have therapeutic activity against Zika virus infection
por: Fernandez, Estefania, et al.
Publicado: (2017)

Covalently linked dengue virus envelope glycoprotein dimers reduce exposure of the immunodominant fusion loop epitope
por: Rouvinski, Alexander, et al.
Publicado: (2017)

Lectin Switching During Dengue Virus Infection
por: Dejnirattisai, Wanwisa, et al.
Publicado: (2011)

Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in Brazil
por: Clemens, Sue Ann Costa, et al.
Publicado: (2021)

Developmental and reproductive safety of AZD1222 (ChAdOx1 nCoV-19) in mice
por: Stebbings, Richard, et al.
Publicado: (2021)

ChAdOx1 nCoV-19 (AZD1222) vaccine candidate significantly reduces SARS-CoV-2 shedding in ferrets
por: Marsh, Glenn A., et al.
Publicado: (2021)

ChAdOx1 nCoV-19 vaccination prevents SARS-CoV-2 pneumonia in rhesus macaques
por: van Doremalen, Neeltje, et al.
Publicado: (2020)

Efficacy of ChAdOx1 vaccines against SARS-CoV-2 Variants of Concern Beta, Delta and Omicron in the Syrian hamster model
por: van Doremalen, Neeltje, et al.
Publicado: (2022)

Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002)
por: Flaxman, Amy, et al.
Publicado: (2021)

Intranasal ChAdOx1 nCoV-19/AZD1222 vaccination reduces shedding of SARS-CoV-2 D614G in rhesus macaques
por: van Doremalen, Neeltje, et al.
Publicado: (2021)

Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial
por: Frater, John, et al.
Publicado: (2021)

ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques
por: van Doremalen, Neeltje, et al.
Publicado: (2020)

Fertility rates and birth outcomes after ChAdOx1 nCoV-19 (AZD1222) vaccination
por: Hillson, Kushalinii, et al.
Publicado: (2021)

Geographical distribution of TTS cases following AZD1222 (ChAdOx1 nCoV-19) vaccination
por: Soboleva, Karina, et al.
Publicado: (2022)

Antibody Response to ChAdOx1 nCoV-19 (AZD1222) Vaccine in Kidney Transplant Recipients
por: Bhadauria, Dharmendra S., et al.
Publicado: (2022)

ChAdOx1 nCoV-19 (AZD1222) protects Syrian hamsters against SARS-CoV-2 B.1.351 and B.1.1.7
por: Fischer, Robert J., et al.
Publicado: (2021)

ChAdOx1 nCoV-19 (AZD1222) protects Syrian hamsters against SARS-CoV-2 B.1.351 and B.1.1.7
por: Fischer, Robert J., et al.
Publicado: (2021)

Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine
por: Falsey, Ann R., et al.
Publicado: (2021)

Alopecia universalis with unusual histopathologic features after vaccination with ChAdOx1 nCoV-19 (AZD1222)
por: Ho, Jonathan D., et al.
Publicado: (2022)

Sensing of Immature Particles Produced by Dengue Virus Infected Cells Induces an Antiviral Response by Plasmacytoid Dendritic Cells
por: Décembre, Elodie, et al.
Publicado: (2014)

Intranasal ChAdOx1 nCoV-19/AZD1222 vaccination reduces viral shedding after SARS-CoV-2 D614G challenge in preclinical models
por: van Doremalen, Neeltje, et al.
Publicado: (2021)

ChAdOx1 nCoV-19 (AZD1222) vaccine-induced Fc receptor binding tracks with differential susceptibility to COVID-19
por: Kaplonek, Paulina, et al.
Publicado: (2023)

SARS-CoV-2 Spike Protein Expression In Vitro and Hematologic Effects in Mice Vaccinated With AZD1222 (ChAdOx1 nCoV-19)
por: Stebbings, Richard, et al.
Publicado: (2022)

Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera
por: Zhou, Daming, et al.
Publicado: (2021)

Vogt-Koyanagi-Harada Syndrome following COVID-19 and ChAdOx1 nCoV-19 (AZD1222) vaccine
por: Saraceno, Janaína Jamile Ferreira, et al.
Publicado: (2021)

Antibody levels in people with diabetes after one dose of the ChAdOx1 nCoV-19 (AZD1222) vaccine
por: Rangsrisaeneepitak, Vimonsri, et al.
Publicado: (2022)

Immune correlates analysis of a phase 3 trial of the AZD1222 (ChAdOx1 nCoV-19) vaccine
por: Benkeser, David, et al.
Publicado: (2023)

ChAdOx1 nCoV-19 protection against SARS-CoV-2 in rhesus macaque and ferret challenge models
por: Lambe, Teresa, et al.
Publicado: (2021)

Antibody evasion by the P.1 strain of SARS-CoV-2
por: Dejnirattisai, Wanwisa, et al.
Publicado: (2021)

AZD1222/ChAdOx1 nCoV-19 vaccination induces a polyfunctional spike protein–specific T(H)1 response with a diverse TCR repertoire
por: Swanson, Phillip A., et al.
Publicado: (2021)

Persistence of the immune response after two doses of ChAdOx1 nCov-19 (AZD1222): 1 year of follow-up of two randomized controlled trials
por: Voysey, Merryn, et al.
Publicado: (2023)

The antibody response to SARS-CoV-2 Beta underscores the antigenic distance to other variants
por: Liu, Chang, et al.
Publicado: (2022)

Risk Factors for Grade 3 to Grade 4 Adverse Reactions to the ChAdOx1 nCoV-19 Vaccine (AZD1222) Against SARS-CoV-2
por: Lee, Sang Won, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_9p7lqavd59cfc6m27b3v50uihe